Bristol-Myers Squibb Company (BMY)

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On November 22, 2006, Bristol-Myers Squibb Company (the “Company”) issued €500,000,000 aggregate principal amount of its 4.375% Notes due 2016 (the “2016 Notes”) and €500,000,000 aggregate principal amount of its 4.625% Notes due 2021 (the “2021 Notes” and, together with the 2016 Notes, the “Notes”). Under their terms, the 2016 Notes bear interest at a rate of 4.375% per year and the 2021 Notes bear interest at a rate of 4.625% per year. The Company will pay interest on the Notes annually on each November 15, beginning November 15, 2007. The 2016 Notes will mature on November 15, 2016 and the 2021 Notes will mature on November 15, 2021. The Notes are unsecured and rank equally with all of the Company’s existing and future unsecured senior indebtedness. The Notes contain certain customary events of default and covenants, including limitations on consolidation, mergers, and sales of assets, limitations on the incurrence of certain liens, and limitations on certain sale and leaseback transactions. The Notes were issued in reliance on exemptions from the registration requirements of the Securities Act of 1933, as amended.

The above description of the Notes is qualified in its entirety by reference to the terms of the 2016 Notes and 2021 Notes, forms of which are attached as Exhibits 4t and 4u, respectively, and incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On December 14, 2005, Bristol-Myers Squibb Company (the “Company”), through a wholly-owned subsidiary, borrowed an additional $500 million against its existing $2.5 billion term loan facility. The discussion contained under Item 1.01 of the Company’s Form 8-K filed August 11, 2005 is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

As previously reported on Form 10-Q for the period ended September 30, 2005, on October 27, 2005, Bristol-Myers Squibb Company (the “Company”), through a wholly-owned subsidiary, borrowed $2.0 billion against its existing $2.5 billion term loan facility. The discussion contained under Item 1.01 of the Company’s Form 8-K filed August 11, 2005 is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.